LCK and glioblastoma: CR13626 (chemical structure was not disclosed by Rottapharm Biotech company), a brand-new brain penetrant small molecule multitarget TKI, inhibited the in vitro activity of several kinases involved in GBM development, e.g., EGFR (IC50 = 3 μM) [174], VEGFR2, Fyn, Lck, Yes, RET and HGK.